Q-omics provides the consensus-scored RPS26P58 profile across patient tissues and cancer cell-line models. RPS26P58 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPS26P58 is differentially expressed in 5, with the highest sampling consensus in LIHC. Additionally, RPS26P58 RNA expression shows 12,887 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, LIHC, and THYM as cancer lineages where RPS26P58 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS26P58 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS26P58 survival associations across molecular data types. RPS26P58 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS26P58 RNA expression–survival associations across cancer types. High RPS26P58 expression shows unfavorable associations in ACC, ESCA, KIRP and LIHC, but favorable associations in KIRC and CESC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RPS26P58 RNA expression.
This table summarizes RPS26P58 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for RPS26P58. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS26P58 shows lower tumor expression in HNSC and higher tumor expression in LIHC, COAD, KIRC and LUSC. The LIHC box plot shows higher RPS26P58 RNA expression in tumor versus normal tissue (log2 FC = +0.231, t-test p = .002).
This table shows molecular features associated with RPS26P58 in patient tissues and cancer cell lines. In patient samples, RPS26P58 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
